A Double-blind, Randomized, Placebo-controlled, Pharmacokinetic, Safety, and Tolerability Study of CSL112 in Adult Subjects With Moderate Renal Impairment and in Healthy Adult Subjects With Normal Renal Function
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2017
At a glance
- Drugs CSL 112 (Primary)
- Indications Myocardial infarction
- Focus Pharmacokinetics
- Sponsors CSL Behring
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 16 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 17 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.